151 related articles for article (PubMed ID: 33880760)
1. Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers.
Xiang Y; Okochi H; Kozachenko I; Sodhi JK; Frassetto LA; Benet LZ
Clin Pharmacol Ther; 2021 Aug; 110(2):480-485. PubMed ID: 33880760
[TBL] [Abstract][Full Text] [Related]
2. Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions.
Chen M; Hu S; Li Y; Gibson AA; Fu Q; Baker SD; Sparreboom A
Drug Metab Dispos; 2020 May; 48(5):419-425. PubMed ID: 32114507
[TBL] [Abstract][Full Text] [Related]
3. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
4. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers.
Cestari RN; Caris JA; Rocha A; Nardotto GHB; de Oliveira RDR; Lanchote VL
J Pharm Biomed Anal; 2020 Apr; 182():113128. PubMed ID: 32004772
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
[TBL] [Abstract][Full Text] [Related]
6. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
[TBL] [Abstract][Full Text] [Related]
7. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.
Chen Y; Zhang W; Huang WH; Tan ZR; Wang YC; Huang X; Zhou HH
Eur J Clin Pharmacol; 2013 Nov; 69(11):1933-8. PubMed ID: 23831870
[TBL] [Abstract][Full Text] [Related]
8. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
Lau YY; Huang Y; Frassetto L; Benet LZ
Clin Pharmacol Ther; 2007 Feb; 81(2):194-204. PubMed ID: 17192770
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
Misaka S; Abe O; Sato H; Ono T; Shikama Y; Onoue S; Yabe H; Kimura J
Eur J Clin Pharmacol; 2018 May; 74(5):601-609. PubMed ID: 29368187
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Qiang F; Lee BJ; Lee W; Han HK
Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
12. Effects of Green Tea Extract on Atorvastatin Pharmacokinetics in Healthy Volunteers.
Abdelkawy KS; Abdelaziz RM; Abdelmageed AM; Donia AM; El-Khodary NM
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):351-360. PubMed ID: 31997084
[TBL] [Abstract][Full Text] [Related]
13. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
Smit JW; Wijnne HJ; Schobben F; Sitsen A; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):89A-96A. PubMed ID: 7604808
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
[TBL] [Abstract][Full Text] [Related]
15. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.
Frymoyer A; Shugarts S; Browne M; Wu AH; Frassetto L; Benet LZ
Clin Pharmacol Ther; 2010 Oct; 88(4):540-7. PubMed ID: 20703222
[TBL] [Abstract][Full Text] [Related]
16. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.
Kyrklund C; Backman JT; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2004 Feb; 57(2):181-7. PubMed ID: 14748817
[TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
Kwara A; Cao L; Yang H; Poethke P; Kurpewski J; Tashima KT; Mahjoub BD; Court MH; Peloquin CA
Pharmacotherapy; 2014 Mar; 34(3):265-71. PubMed ID: 24420746
[TBL] [Abstract][Full Text] [Related]
19. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
Shaik MN; Hee B; Wei H; LaBadie RR
Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
